CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
None of these measures proved effective in significantly reducing opium use. In the following years, opioids, cocaine, and cannabis were associated with various ethnic minorities and targeted in other local jurisdictions. In 1908, Hamilton Wright was appointed United States Opium Commissioner. His wife, Elizabeth Washburn Wright, carried on much of his anti-opium campaign after his death in 1917. In 1906, the Pure Food and Drug Act, also known as the Wiley Act, addressed problems with tainted and adulterated food in the growing industrial food system, and with drug quality, by mandating ingredient labels and prohibiting false or misleading labeling. For drugs, a listing of active ingredients was required; a set of drugs deemed addictive or dangerous, that included opium, morphine, cocaine, caffeine, and cannabis, was specified. Oversight of the act was assigned to the US Department of Agriculture's Bureau of Chemistry, which evolved into the Food and Drug Administration in 1930.
=== Later years === With the restoration of democracy in 1974, Zervas was able to contribute once more to research and educational policy. As previously, refusing to take a salary for these positions, he served a second time as the President of the Greek Atomic Energy Commission (1974–1975) and then as the President of the National Hellenic Research Foundation (1975–1979). Zervas had suffered from periodic issues with respiratory health throughout his adult life, but in his final years the situation deteriorated. The extended use of phosgene in his research has been implicated as the cause of this chronic pulmonary disease. He showed perseverance and a pleasant attitude despite his health issues, continuing to attend meetings of the Academy of Athens until the very end of his life. This came in the summer of 1980 after an acute pulmonary episode, which lasted three weeks before he died at the age of 78.
10-Methacryloyloxydecyl dihydrogen phosphate (10-MDP, MDP Monomer) is a chemical compound used in dental adhesive materials. This organophosphate monomer was developed in 1981 by the Japanese company Kuraray for the preparation of dental adhesion polymers
=== Synthesis === A chemical synthesis of mirtazapine has been published. The first step of synthesis is a condensation reaction between 2-chloro-3-cyanopyridine (1) and 1-methyl-3-phenylpiperazine (2) to give cyano compound 3. Hydrolysis of the cyanide group to the corresponding carboxylic acid (4), reduction to the alcohol (5) allows for mirtazapine (6) to be synthesised via an acid mediated cyclisation.
Lungs and the entire respiratory system The entire digestive system including the liver Metabolism Skin, directly and indirectly through the intestine Hematopoietic organs It was generally described as a food capable of regenerating a weakened, emaciated, impoverished organism in an unusually short time, allowing the body to achieve better resistance. It was used by the Asian (Mongolian) equestrian peoples often as the only source of food for long periods and during high physical exertion, without the body developing symptoms of deficiency. Under Genghis-chan, the Mongols established a large empire. They moved on their horses across the steppes, deserts, and mountains and covered large distances, and for long periods they lived mainly on the milk of their mares, both fresh and fermented (kumyss). Around 1850, various Russian doctors observed the habits of the shepherds of the Baskirian steppe. They reported that the Basic and Tatars spent the winter in very unfavorable environmental conditions, with temperatures down to minus 60 °C, severe winter storms, and very little or no food. Weakened nomads regained their strength unusually quickly as soon as they fed on mare's milk. Russian doctors observed in the 19th century that tuberculosis was practically non-existent among the steppe nomads. Doctors attributed it to fermented mare milk as the staple food of the steppe people. When this became known in Russia, a migration of tuberculosis patients from Russia to the steppes began. The treatment was initially "wild", without medical supervision.
Sources: en.wikipedia.org
Pan genomics is a concept introduced in 2005 by Tettelin and Medini. Pan genome is the complete gene repertoire of a particular monophyletic taxonomic group. Although initially applied to closely related strains of a species, it can be applied to a larger context like genus, phylum, etc. It is divided in two parts: the Core genome, a set of genes common to all the genomes under study (often housekeeping genes vital for survival), and the Dispensable/Flexible genome: a set of genes not present in all but one or some genomes under study. A bioinformatics tool BPGA can be used to characterize the Pan Genome of bacterial species.
Going from 16.7% to 21.7% of the labour force, the rate of unemployment has increased between 2007 and 2017, and it remains higher than in the rest of the country (13.9%). The proportion Le Havre people in short-term employment (CDD and interim work) is higher than the national average. Finally, the proportion of Le Havre people with a degree from higher education dramatically increased from 17.3% in 2007 to 23.2% in 2017 against 29.9% for entire France.
coli on minimal medium lacking histidine (NM selective medium) that is usually supplemented with varying concentrations of 3-amino-triazole (3-AT), a competitive inhibitor of HIS3. HIS3 encodes a protein required for histidine biosynthesis and thus only those cells containing bait-prey combinations that activate the reporter genes will be able to grow. Manipulating 3-AT concentrations allows for the characterization of binding stringencies. In this way, researches can gauge how strongly bait binds its prey (correlated with the level of expression of HIS3) and thus determines which nucleotide binding-sites have strong or weak preferences for a given base. In other words, if cells can grow despite a high concentration of 3-AT, bait-prey binding must be of high enough stringency to drive reporter gene expression (HIS3) at a sufficient level to overcome the resulting competitive inhibition. Finally, positive clones are sequenced and examined with preexisting motif-finding tools (ex, MEME, BioProspector).
Romania is a country in Central and Southeastern Europe. It lies on the lower course of the Danube, north of the Balkan Peninsula, and on the northwestern shore of the Black Sea. It borders Ukraine to the north and east, Hungary to the west, Serbia to the southwest, Bulgaria to the south, Moldova to the east, and the Black Sea to the southeast. It is the twelfth-largest country in Europe by area, covering 238,397 km2 (92,046 mi2), and the sixth-most populous member state of the European Union, with 19 million inhabitants. Administratively, Romania is divided into 41 counties, the largest being Timiș County. The capital, largest city and economic centre is Bucharest. Other major cities and metropolitan areas include Timișoara (TMA), Iași (IMA), Constanța (CMA) and Cluj-Napoca (CMA). Romania was settled during the Lower Paleolithic, later becoming Dacia before Trajan's Dacian Wars and Romanisation. The modern Romanian state was formed in 1859 with the unification of Moldavia and Wallachia under Alexandru Ioan Cuza, becoming the Kingdom of Romania in 1881 under Carol I of Romania. Romania gained independence from the Ottoman Empire in 1877, formalised by the Treaty of Berlin. After World War I, Transylvania, Banat, Bukovina, and Bessarabia joined the Old Kingdom, forming Greater Romania, which reached its largest territorial extent. In 1940, under Axis pressure, Romania lost territories to Hungary, Bulgaria, and the Soviet Union. Following the Act of 23 August, Romania switched sides to join the Allies.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.